Your Health, We Care
In June 2024, Roche announced that the European Commission and the US FDA had approved Alectinib (trade name Alecensa) as an adjuvant therapy for adult ALK positive NSCLC patients at high risk of recurrence after tumor resection.
With the deepening of research on Alectinib, its therapeutic potential in other types of tumors and its combination therapy with other drugs may be explored in the future.
